This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
in the development and manufacturing of protein drugs. The
Company operates its business under two segments. The
Biosimilar segment develops and manufactures biosimilar
products used to treat breast cancer, rheumatoid arthritis
disease, Crohn's disease, Hodgkin's lymphoma, colorectal
cancer, rheumatoid arthritis, respiratory syncytial virus, colon
cancer and others. The New Biopharmaceutical Development
segment is engaged in the development of
biopharmaceuticals, such as monoclonal antibodies against
rabies and breast cancers, pandemics and seasonal influenza viruses, through co-development with multinational
pharmaceutical and biotechnology companies.
Company's lead product CreaVax-RCC Inj. is indicated for the treatment of metastatic renal cell carcinoma.
Development status of lead candidates: EG-Mirotin (diabetic retinopathy, EU, Phase I), EG-HPV (HPV Vaccine, Korea, Phase I), EG-Decorin (pressure ulcer/bedsore, Korea, Phase I/II).
EG-Mirotin (therapeutic agent for diabetic retinopathy) completed pre-clinical trials in Europe/Korea and is currently in EU Phase I trials. They are looking for licensing partners for global territorial rights.
EG-HPV and EG-Decorin?s domestic territorial rights have been licensed out to CKD Pharma and Huons respectively (both are leading pharmaceutical companies in Korea). They are actively looking for licensing partners for global regions ex-Korea.